CNSP
CNS Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
CNS Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for CNS Pharmaceuticals, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for CNS Pharmaceuticals, Inc..
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals, Inc.
4.45
+0.06 · +1.37%
post 4.14 −6.93%
| Manager | Value | % base | |
|---|---|---|---|
| Stonepine | $6.4M | 84.93% | +2106.43% |
| Ikarian Capital | $649,267 | 8.57% | +196.38% |
| ADAR1 | $334,600 | 4.42% | new |
| Boothbay Fund | $64,645 | 0.85% | 0.00% |
| Vanguard Fiduciary Trustindex-like | $48,880 | 0.65% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Stonepine | $6.4M | 84.93% | +2106.43% |
| Ikarian Capital | $649,267 | 8.57% | +196.38% |
| ADAR1 | $334,600 | 4.42% | new |
| Boothbay Fund | $64,645 | 0.85% | 0.00% |
| Vanguard Fiduciary Trustindex-like | $48,880 | 0.65% | new |
+1123.46%
shares held · 7 largest managers
Expected move
No implied move.